# Vitamin D Supplementation During Neoadjuvant Chemotherapy for Breast Cancer Improves Pathological Complete Response: A Prospective Randomized Clinical Trial

**Autores:** Enver Özkurt, Cetin Ordu, Tolga Özmen et al.
**Revista:** World J Surg (2025)
**PMID:** 40229998 | **PMCID:** PMC12134193
**DOI:** [10.1002/wjs.12587](https://doi.org/10.1002/wjs.12587)
**Fuente:** PubMed Central (open access full-text)

## Relevancia
Ensayo aleatorizado prospectivo (n=227) sobre suplementación con vitamina D3 (50,000 UI/sem) durante QT neoadyuvante. Aumenta significativamente la pCR global (OR 2.33; IC95% 1.20-4.53; p=0.013) aunque el efecto sobre pCR axilar fue solo casi significativo. Tangencial al tema central (categorizado como 04_otros_tumores por tratarse de una intervención farmacológica complementaria).

## Abstract
Achieving a pCR serves as a biomarker indicating enhanced overall survival for breast cancer patients undergoing NST. Vitamin D enhances the antitumor effect of chemotherapeutics as demonstrated in cancer cells and animal models. In this prospective randomized clinical study, we aim to investigate the effect of oral vitamin D supplementation during neoadjuvant systemic therapy (NST) on pathologic complete response (pCR).

Between June 2019 and June 2023, an oral form of 50,000 IU vitamin D3 (cholecalciferol) replacement was administered once a week during NST for the study group.

There were 114 (50.2%) cases in the study group and 113 (49.8%) in the control group (totally 227 cases). Factors that positively influenced pCR were higher clinical T stage, higher AJCC clinical stage, Estrogen receptor negativity, progesterone receptor negativity, human epidermal growth factor receptor 2 positivity, high Ki-67 expression (≥ 20%), hormone negative molecular subtypes, and vitamin D intake in univariate analysis. In the multivariate analysis, factors significantly affecting pCR were vitamin D intake (OR: 2.33, 95% CI 1.20-4.53; p = 0.013), hormone receptor negativity (OR: 2.22, 95% CI 1.11-4.43; p = 0.024), and Ki-67 ≥ 20% (OR: 3.27, 95% CI 1.03-10.34; p = 0.044).

This is the first and only study to compare the effect of oral vitamin D supplementation on pCR during NST. Vitamin D supplementation during NST has a significant effect on pCR in breast cancer patients. Although this effect is not significant for axillary pCR, there is an almost significant correlation.

ClinicalTrials.gov (Identifier: NCT03986268).

## Texto completo
Texto completo disponible en PMC: [PMC12134193](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12134193/). El estudio describe un ensayo aleatorizado prospectivo realizado en Turquía sobre suplementación con vitamina D durante QT neoadyuvante en cáncer de mama. El análisis multivariado identifica vitamina D, receptor hormonal negativo y Ki-67 ≥20% como factores independientes asociados con pCR. Limitación: efecto sobre pCR axilar específica solo casi significativo.

---
*Datos de PubMed. Citar: doi 10.1002/wjs.12587*
